Maurizio R Averna
Overview
Explore the profile of Maurizio R Averna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Luca L, Temporelli P, Gulizia M, Gonzini L, Ammaturo T, Tedesco L, et al.
Nutr Metab Cardiovasc Dis
. 2023 Oct;
33(12):2398-2405.
PMID: 37788956
Background And Aim: Elevated triglyceride (TG) levels seem to identify subjects at increased cardiovascular risk, independent of LDL-C levels. We sought to evaluate the predictive role of hypertriglyceridemia, defined as...
2.
3.
Cefalu A, Spina R, Noto D, Rabacchi C, Giammanco A, Simone M, et al.
J Clin Lipidol
. 2022 May;
16(4):530-537.
PMID: 35589500
Background: Primary Hypobetalipoproteinemias (HBL) are a group of dominant and recessive monogenic genetic disorders caused by mutations in APOB, PCSK9, ANGPTL3, MTTP, Sar1b genes and characterized by plasma levels of...
4.
Giammanco A, Spina R, Fayer F, Barbagallo C, Noto D, Cefalu A, et al.
Intern Med J
. 2021 Apr;
51(4):585-590.
PMID: 33890362
Familial defective apolipoprotein (apo) B (FDB) and familial hypercholesterolaemia (FH) are the two common genetic conditions that cause hypercholesterolaemia. R3531C mutation of the APOB gene is a rare cause of...
5.
Noto D, Cefalu A, Martinelli N, Giammanco A, Spina R, Barbagallo C, et al.
Nutr Metab Cardiovasc Dis
. 2021 Apr;
31(5):1542-1547.
PMID: 33810964
Background And Aims: Novel genetic determinants associated with coronary artery disease (CAD) have been discovered by genome wide association studies. Variants encompassing the CELSR2- PSRC1-SORT1 gene cluster have been associated...
6.
Noto D, Giammanco A, Spina R, Fayer F, Cefalu A, Averna M
PLoS One
. 2021 Mar;
16(3):e0247402.
PMID: 33661949
SREBP1 and 2, are cholesterol sensors able to modulate cholesterol-related gene expression responses. SREBPs binding sites are characterized by the presence of multiple target sequences as SRE, NFY and SP1,...
7.
Valenti V, Noto D, Giammanco A, Fayer F, Spina R, Altieri G, et al.
Atherosclerosis
. 2019 Oct;
292:209-214.
PMID: 31564372
Background And Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low density lipoprotein receptor (LDLR) through the LDLR epidermal growth factor-like repeat A (EGF-A) domain and induces receptor internalization...
8.
Ben-Zeev O, Hosseini M, Lai C, Ehrhardt N, Wong H, Cefalu A, et al.
J Lipid Res
. 2019 Sep;
60(9):1641.
PMID: 31474618
No abstract available.
9.
Giammanco A, Cefalu A, Noto D, Averna M
Curr Med Chem
. 2019 Jan;
27(23):3773-3783.
PMID: 30663562
Background: Lomitapide (Juxtapid® in US and Lojuxta® in Europe) is the first developed inhibitor of the Microsomal Triglyceride Transfer Protein (MTP) approved as a novel drug for the management of...
10.
Noto D, Giammanco A, Barbagallo C, Cefalu A, Averna M
Cardiovasc Res
. 2018 Jun;
114(12):1595-1604.
PMID: 29931148
Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the...